Compare AstraZeneca plc (AZN) vs Intuit Inc. (INTU) Price & Performance

AstraZeneca plcTrade

Intuit Inc.Trade

Price performance (Past 24H)

Key statistics

AstraZeneca plc vs Intuit Inc. — how do they compare? AstraZeneca plc trades at $157.51 (market cap $245.16B), while Intuit Inc. trades at $338.72 (market cap $91.56B). The key difference: AstraZeneca plc is far larger — about 2.7× Intuit Inc.'s market cap, and AstraZeneca plc pays the higher dividend (2.02%). Which is the better fit depends on your goals.

	AZN	INTU
Market Cap	$245.16B	$91.56B
Sector	Health	Technology
52-Week High	$209.48	$717.21
52-Week Low	$147.06	$255.07
Enterprise Value	$272.43B	$90.01B
Dividend Yield	2.02%	1.43%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AstraZeneca plc

AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.

Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.

Intuit Inc.

Intuit (INTU) trades at $336.44, up 0.6% today, with a bullish technical signal from moving averages and oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $12.8 exceeding expectations. Revenue grew to $18.83B in 2025, with a net income margin of 21.91%. However, the stock faces headwinds from multiple law firm investigations into securities fraud allegations related to pricing issues, contributing to a 20% stock drop recently noted by Forbes on June 2, 2026.

The outlook is mixed: robust fundamentals and a consensus price target of $402.26 suggest upside, but legal risks and overbought RSI levels near 81.6 pose near-term challenges. Investors should weigh the company's AI-driven growth in financial software against regulatory scrutiny and competitive pressures in the fintech space.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

AZN

BioCryst hits profitability with strong Q2 revenue, sparking takeover interest in rare disease biotech.24/7 Wall Street · 2 days agoBullish View details →

INTU

Intuit rated Buy as QuickBooks and TurboTax drive growth despite AI concerns and stock dipSeeking Alpha · 6 hours agoBullish Intuit remains a Buy despite 24% drop and AI concerns, with strong growth and raised revenue guidance.Seeking Alpha · 14 hours agoBullish Intuit remains a Buy despite near-term volatility from restructuring and cautious sentiment.Seeking Alpha · 1 day agoBullish View details →

About AstraZeneca plc

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

About Intuit Inc.

Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.